Iterum Therapeutics (ITRM)
(Delayed Data from NSDQ)
$1.21 USD
+0.04 (3.42%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $1.21 0.00 (0.00%) 6:52 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
Iterum Therapeutics PLC [ITRM]
Reports for Purchase
Showing records 41 - 60 ( 73 total )
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Sulopenem NDA for uUTI Accepted With July 25 PDUFA Date; Awaiting Commercial Plan to Solidify; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
CSO Resigns, Added to the Board; Potential Sulopenem NDA Acceptance Next Month; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Sulopenem NDA Submitted for Quinolone-Resistant uUTI; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
3Q20 Recap; Sulopenem uUTI NDA Filing Imminent for 2H21 PDUFA
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Regulatory Pathway Confirmed for Sulopenem in Subset of uUTI, but Near-Term Overhangs Remain
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Awaiting FDA Meeting at End of 3Q20 to Elucidate Sulopenem''s U.S. Regulatory Path; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Sulopenem Failed Phase 3 cUTI Trial; Downgrade to Neutral and Remove PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
1Q20 Recap: Imminent Make or Break Readouts in UTI; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
4Q Recap: Data Catalysts Imminent With Two Phase 3 Readouts; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Awaiting Pivotal UTI Data for Sulopenem in 1Q20; Affirm Buy, Reduce PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E